<!DOCTYPE html><html lang="en" ><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"><meta name="theme-color" media="(prefers-color-scheme: light)" content="#f7f7f7"><meta name="theme-color" media="(prefers-color-scheme: dark)" content="#1b1b1e"><meta name="apple-mobile-web-app-capable" content="yes"><meta name="apple-mobile-web-app-status-bar-style" content="black-translucent"><meta name="viewport" content="width=device-width, user-scalable=no initial-scale=1, shrink-to-fit=no, viewport-fit=cover" ><meta name="generator" content="Jekyll v4.3.2" /><meta property="og:title" content="Retrospective Study on the Use of Different Protocols for Repeated Transarterial Chemoembolization in the Treatment of Patients with Hepatocellular Carcinoma" /><meta property="og:locale" content="en" /><meta name="description" content="Purpose" /><meta property="og:description" content="Purpose" /><link rel="canonical" href="https://clinicaltree.github.io/posts/retrospective-study-on-the-use-of-different-protocols-for-repeated-transarterial-chemoembolization-i/" /><meta property="og:url" content="https://clinicaltree.github.io/posts/retrospective-study-on-the-use-of-different-protocols-for-repeated-transarterial-chemoembolization-i/" /><meta property="og:site_name" content="Radiology Tree" /><meta property="og:type" content="article" /><meta property="article:published_time" content="2012-03-31T17:00:00+00:00" /><meta name="twitter:card" content="summary" /><meta property="twitter:title" content="Retrospective Study on the Use of Different Protocols for Repeated Transarterial Chemoembolization in the Treatment of Patients with Hepatocellular Carcinoma" /><meta name="twitter:site" content="@twitter_username" /><meta name="google-site-verification" content="RFHVRgQqK0eGjftEMCTDhsDrR8cJ_ZYcfCX52gXW8KM" /> <script type="application/ld+json"> {"@context":"https://schema.org","@type":"BlogPosting","dateModified":"2023-04-10T02:43:55+00:00","datePublished":"2012-03-31T17:00:00+00:00","description":"Purpose","headline":"Retrospective Study on the Use of Different Protocols for Repeated Transarterial Chemoembolization in the Treatment of Patients with Hepatocellular Carcinoma","mainEntityOfPage":{"@type":"WebPage","@id":"https://clinicaltree.github.io/posts/retrospective-study-on-the-use-of-different-protocols-for-repeated-transarterial-chemoembolization-i/"},"url":"https://clinicaltree.github.io/posts/retrospective-study-on-the-use-of-different-protocols-for-repeated-transarterial-chemoembolization-i/"}</script><title>Retrospective Study on the Use of Different Protocols for Repeated Transarterial Chemoembolization in the Treatment of Patients with Hepatocellular Carcinoma | Radiology Tree</title><link rel="apple-touch-icon" sizes="180x180" href="/assets/img/favicons/apple-touch-icon.png"><link rel="icon" type="image/png" sizes="32x32" href="/assets/img/favicons/favicon-32x32.png"><link rel="icon" type="image/png" sizes="16x16" href="/assets/img/favicons/favicon-16x16.png"><link rel="manifest" href="/assets/img/favicons/site.webmanifest"><link rel="shortcut icon" href="/assets/img/favicons/favicon.ico"><meta name="apple-mobile-web-app-title" content="Radiology Tree"><meta name="application-name" content="Radiology Tree"><meta name="msapplication-TileColor" content="#da532c"><meta name="msapplication-config" content="/assets/img/favicons/browserconfig.xml"><meta name="theme-color" content="#ffffff"><link rel="preconnect" href="https://fonts.googleapis.com" ><link rel="dns-prefetch" href="https://fonts.googleapis.com" ><link rel="preconnect" href="https://fonts.gstatic.com" crossorigin><link rel="dns-prefetch" href="https://fonts.gstatic.com" crossorigin><link rel="preconnect" href="https://fonts.googleapis.com" ><link rel="dns-prefetch" href="https://fonts.googleapis.com" ><link rel="preconnect" href="https://cdn.jsdelivr.net" ><link rel="dns-prefetch" href="https://cdn.jsdelivr.net" ><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Lato&family=Source+Sans+Pro:wght@400;600;700;900&display=swap"><link rel="preconnect" href="https://www.google-analytics.com" crossorigin="use-credentials"><link rel="dns-prefetch" href="https://www.google-analytics.com"><link rel="preconnect" href="https://www.googletagmanager.com" crossorigin="anonymous"><link rel="dns-prefetch" href="https://www.googletagmanager.com"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/bootstrap@4.6.2/dist/css/bootstrap.min.css"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/@fortawesome/fontawesome-free@6.2.1/css/all.min.css"><link rel="stylesheet" href="/assets/css/style.css"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/tocbot@4.20.1/dist/tocbot.min.css"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/magnific-popup@1.1.0/dist/magnific-popup.min.css"> <script src="https://cdn.jsdelivr.net/npm/jquery@3.6.1/dist/jquery.min.js"></script> <script type="text/javascript"> class ModeToggle { static get MODE_KEY() { return "mode"; } static get MODE_ATTR() { return "data-mode"; } static get DARK_MODE() { return "dark"; } static get LIGHT_MODE() { return "light"; } static get ID() { return "mode-toggle"; } constructor() { if (this.hasMode) { if (this.isDarkMode) { if (!this.isSysDarkPrefer) { this.setDark(); } } else { if (this.isSysDarkPrefer) { this.setLight(); } } } let self = this; /* always follow the system prefers */ this.sysDarkPrefers.addEventListener('change', () => { if (self.hasMode) { if (self.isDarkMode) { if (!self.isSysDarkPrefer) { self.setDark(); } } else { if (self.isSysDarkPrefer) { self.setLight(); } } self.clearMode(); } self.notify(); }); } /* constructor() */ get sysDarkPrefers() { return window.matchMedia("(prefers-color-scheme: dark)"); } get isSysDarkPrefer() { return this.sysDarkPrefers.matches; } get isDarkMode() { return this.mode === ModeToggle.DARK_MODE; } get isLightMode() { return this.mode === ModeToggle.LIGHT_MODE; } get hasMode() { return this.mode != null; } get mode() { return sessionStorage.getItem(ModeToggle.MODE_KEY); } /* get the current mode on screen */ get modeStatus() { if (this.isDarkMode || (!this.hasMode && this.isSysDarkPrefer)) { return ModeToggle.DARK_MODE; } else { return ModeToggle.LIGHT_MODE; } } setDark() { $('html').attr(ModeToggle.MODE_ATTR, ModeToggle.DARK_MODE); sessionStorage.setItem(ModeToggle.MODE_KEY, ModeToggle.DARK_MODE); } setLight() { $('html').attr(ModeToggle.MODE_ATTR, ModeToggle.LIGHT_MODE); sessionStorage.setItem(ModeToggle.MODE_KEY, ModeToggle.LIGHT_MODE); } clearMode() { $('html').removeAttr(ModeToggle.MODE_ATTR); sessionStorage.removeItem(ModeToggle.MODE_KEY); } /* Notify another plugins that the theme mode has changed */ notify() { window.postMessage({ direction: ModeToggle.ID, message: this.modeStatus }, "*"); } flipMode() { if (this.hasMode) { if (this.isSysDarkPrefer) { if (this.isLightMode) { this.clearMode(); } else { this.setLight(); } } else { if (this.isDarkMode) { this.clearMode(); } else { this.setDark(); } } } else { if (this.isSysDarkPrefer) { this.setLight(); } else { this.setDark(); } } this.notify(); } /* flipMode() */ } /* ModeToggle */ const modeToggle = new ModeToggle(); </script><body data-topbar-visible="true"><div id="sidebar" class="d-flex flex-column align-items-end"><div class="profile-wrapper text-center"><div id="avatar"> <a href="/" class="mx-auto"> <img src="https://storage.googleapis.com/clinicalpub.com/images/favicon.png" alt="avatar" onerror="this.style.display='none'"> </a></div><div class="site-title"> <a href="/">Radiology Tree</a></div><div class="site-subtitle font-italic">Update every day the best and the lastest articles, books, journals, clinical cases, videos, images... for radiologist</div></div><ul class="w-100"><li class="nav-item"> <a href="/" class="nav-link"> <i class="fa-fw fas fa-home ml-xl-3 mr-xl-3 unloaded"></i> <span>HOME</span> </a><li class="nav-item"> <a href="/categories/" class="nav-link"> <i class="fa-fw fas fa-stream ml-xl-3 mr-xl-3 unloaded"></i> <span>CATEGORIES</span> </a><li class="nav-item"> <a href="/tags/" class="nav-link"> <i class="fa-fw fas fa-tag ml-xl-3 mr-xl-3 unloaded"></i> <span>TAGS</span> </a><li class="nav-item"> <a href="/archives/" class="nav-link"> <i class="fa-fw fas fa-archive ml-xl-3 mr-xl-3 unloaded"></i> <span>ARCHIVES</span> </a><li class="nav-item"> <a href="/about/" class="nav-link"> <i class="fa-fw fas fa-info-circle ml-xl-3 mr-xl-3 unloaded"></i> <span>ABOUT</span> </a></ul><div class="sidebar-bottom mt-auto d-flex flex-wrap justify-content-center align-items-center"> <button class="mode-toggle btn" aria-label="Switch Mode"> <i class="fas fa-adjust"></i> </button> <span class="icon-border"></span> <a href="https://github.com/clinicaltree" aria-label="github" target="_blank" rel="noopener noreferrer"> <i class="fab fa-github"></i> </a> <a href="https://twitter.com/twitter_username" aria-label="twitter" target="_blank" rel="noopener noreferrer"> <i class="fab fa-twitter"></i> </a> <a href="javascript:location.href = 'mailto:' + ['clinicalpub.team','gmail.com'].join('@')" aria-label="email" > <i class="fas fa-envelope"></i> </a> <a href="/feed.xml" aria-label="rss" > <i class="fas fa-rss"></i> </a></div></div><div id="topbar-wrapper"><div id="topbar" class="container d-flex align-items-center justify-content-between h-100 pl-3 pr-3 pl-md-4 pr-md-4"> <span id="breadcrumb"> <span> <a href="/"> Home </a> </span> <span>Retrospective Study on the Use of Different Protocols for Repeated Transarterial Chemoembolization in the Treatment of Patients with Hepatocellular Carcinoma</span> </span> <i id="sidebar-trigger" class="fas fa-bars fa-fw"></i><div id="topbar-title"> Post</div><i id="search-trigger" class="fas fa-search fa-fw"></i> <span id="search-wrapper" class="align-items-center"> <i class="fas fa-search fa-fw"></i> <input class="form-control" id="search-input" type="search" aria-label="search" autocomplete="off" placeholder="Search..."> </span> <span id="search-cancel" >Cancel</span></div></div><div id="main-wrapper" class="d-flex justify-content-center"><div id="main" class="container pl-xl-4 pr-xl-4"><div class="row"><div id="core-wrapper" class="col-12 col-lg-11 col-xl-9 pr-xl-4"><div class="post pl-1 pr-1 pl-md-2 pr-md-2"><h1 data-toc-skip>Retrospective Study on the Use of Different Protocols for Repeated Transarterial Chemoembolization in the Treatment of Patients with Hepatocellular Carcinoma</h1><div class="post-meta text-muted"> <span> Posted <em class="" data-ts="1333213200" data-df="ll" data-toggle="tooltip" data-placement="bottom"> Mar 31, 2012 </em> </span> <span> Updated <em class="" data-ts="1681094635" data-df="ll" data-toggle="tooltip" data-placement="bottom"> Apr 10, 2023 </em> </span><div class="d-flex justify-content-between"> <span> By <em> <a href="">Thomas J. Vogl MD</a> </em>, <em> <a href="">Nagy N.N. Naguib MSc</a> </em>, <em> <a href="">Nour-Eldin A. Nour-Eldin MSc MD</a> </em>, <em> <a href="">Parviz Farshid MBBch</a> </em>, <em> <a href="">Thomas Lehnert MD</a> </em>, <em> <a href="">Tatjana Gruber-Rouh MD</a> </em>, <em> <a href="">Katharina Sophia Engels MED</a> </em> </span><div> <span class="readtime" data-toggle="tooltip" data-placement="bottom" title="1438 words"> <em>7 min</em> read</span></div></div></div><div class="post-content"><h2 id="purpose"><span class="mr-2">Purpose</span><a href="#purpose" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>To evaluate local tumor control and survival rate after repeated transarterial chemoembolization using two different protocols in hepatocellular carcinoma (HCC) patients.</p><h2 id="materials-and-methods"><span class="mr-2">Materials and Methods</span><a href="#materials-and-methods" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>A total of 190 patients (mean, 68 years) with HCC were repeatedly treated with transarterial chemoembolization in 4-week intervals. The chemotherapy protocol consisted of mitomycin C alone ( <em>n</em> = 111) and mitomycin C with gemcitabine ( <em>n</em> = 79). Embolization was performed with lipiodol and microspheres. Tumor response was evaluated by magnetic resonance imaging using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Survival rates were calculated using Kaplan-Meier method.</p><h2 id="results"><span class="mr-2">Results</span><a href="#results" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>In the mitomycin C–only group, we observed partial response in 38.8% (43/111), stable disease in 27% (30/111), and progressive disease in 34.2% (38/111). In the mitomycin C/gemcitabine group ( <em>n</em> = 79), partial response was observed in 43% (34/79), stable disease in 16.5% (13/79) and progressive disease in 40.5% (32/79). The overall 1- and 2-year survival rates were 56% and 28%, respectively. The overall median survival time from the start of transarterial chemoembolization treatment was 15 months. The median survival of patients treated with mitomycin C was 16.5 months and it was 12 months for patients treated with a combination of mitomycin C and gemcitabine. No statistically significant difference between the two groups was observed ( <em>P</em> = .7).</p><h2 id="conclusion"><span class="mr-2">Conclusion</span><a href="#conclusion" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>Chemoembolization is an effective minimally invasive therapy option for palliative treatment of HCC patients. Mitomycin C only proves to be effective, the addition of gemcitabine was not advantageous.</p><p>Hepatocellular carcinoma (HCC) is one of the most common solid-organ malignancies worldwide. Moreover, recent data suggest that the incidence and mortality of HCC in western nations is on the rise, and HCC is currently the leading cause of death among cirrhotic patients .</p><p>However, most HCC patients are unresectable at diagnosis because of multicentricity, large tumor size or a poor hepatic functional reserve due to preexisting cirrhosis, or they are not transplantable because of an advanced tumor stage or severe comorbidity . Therefore transarterial chemoembolization seems to be more important as a treatment strategy .</p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="materials-and-methods-1"><span class="mr-2">Materials and methods</span><a href="#materials-and-methods-1" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><h2 id="patients"><span class="mr-2">Patients</span><a href="#patients" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p>Table 1</p><p>Baseline Characteristics of Patients in the Mitomycin C only and Mitomycin C with Gemcitabine Group</p><p>Mitomycin <em>n</em> = 111 Mitomycin and gemcitabine <em>n</em> = 79 Age, mean years 69 67 Men, women 84, 27 53, 26 Child-Pugh class A 62 27 B 14 3 Transarterial chemoembolization sessions 477 458 Treatment Palliative 91 (82%) 53 (67%)<em>P</em> = .0827 Neoadjuvant 20 (18%) 26 (33%)<em>P</em> = .0730 Mean diameter of nodule 5.42 cm 3.9 cm</p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="indication-and-contraindication-for-transarterial-chemoembolization"><span class="mr-2">Indication and Contraindication for Transarterial Chemoembolization</span><a href="#indication-and-contraindication-for-transarterial-chemoembolization" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="chemoembolization-therapy"><span class="mr-2">Chemoembolization Therapy</span><a href="#chemoembolization-therapy" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="patient-evaluation-and-follow-up"><span class="mr-2">Patient Evaluation and Follow-up</span><a href="#patient-evaluation-and-follow-up" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="quantitative-and-statistical-evaluation"><span class="mr-2">Quantitative and Statistical Evaluation</span><a href="#quantitative-and-statistical-evaluation" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="results-1"><span class="mr-2">Results</span><a href="#results-1" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><h2 id="mri-findings"><span class="mr-2">MRI Findings</span><a href="#mri-findings" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="survival-analysis"><span class="mr-2">Survival Analysis</span><a href="#survival-analysis" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://storage.googleapis.com/dl.dentistrykey.com/clinical/RetrospectiveStudyontheUseofDifferentProtocolsforRepeatedTransarterialChemoembolizationintheTreatmentofPatientswithHepatocellularCarcinoma/0_1s20S1076633211006131.jpg" class="popup img-link "><img data-src="https://storage.googleapis.com/dl.dentistrykey.com/clinical/RetrospectiveStudyontheUseofDifferentProtocolsforRepeatedTransarterialChemoembolizationintheTreatmentofPatientswithHepatocellularCarcinoma/0_1s20S1076633211006131.jpg" alt="Figure 1, Kaplan-Meier survival curve. ( Curve a ) Survival data of all patients ( n = 111) with liver lesions after transarterial chemoembolization with mitomycin C. Median survival time was 16.5 months. ( Curve b ) 79 patients were treated with mitomycin C and gemcitabine. Median survival time was 12 months." class="lazyload" data-proofer-ignore></a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://storage.googleapis.com/dl.dentistrykey.com/clinical/RetrospectiveStudyontheUseofDifferentProtocolsforRepeatedTransarterialChemoembolizationintheTreatmentofPatientswithHepatocellularCarcinoma/1_1s20S1076633211006131.jpg" class="popup img-link "><img data-src="https://storage.googleapis.com/dl.dentistrykey.com/clinical/RetrospectiveStudyontheUseofDifferentProtocolsforRepeatedTransarterialChemoembolizationintheTreatmentofPatientswithHepatocellularCarcinoma/1_1s20S1076633211006131.jpg" alt="Figure 2, Kaplan-Meier survival curve. Median survival time of the palliative group was 12 months, of the neoadjuvant group 24 months. ( Curve a ) Survival data of the palliative group patients ( n = 144). ( Curve b ) Survival data of the neoadjuvant group patients ( n = 46)." class="lazyload" data-proofer-ignore></a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="discussion"><span class="mr-2">Discussion</span><a href="#discussion" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="references"><span class="mr-2">References</span><a href="#references" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><ul><li><p>1. Bruix J., Sala M., Llovet J.: Chemoembolization for hepatocellular carcinoma. Gastroenterology 2004; 127: pp. 179-188.</p><li><p>2. Taylor-Robinson S.D., Foster G.R., Arora S., et. al.: Increase in primary liver cancer in the UK, 1979–94. Lancet 1997; 350: pp. 1142-1143.</p><li><p>3. Llovet J., Sala M.: Non-surgical therapies of hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2005; 17: pp. 505-513.</p><li><p>4. Llovet J., Burroughs A., Bruix J.: Hepatocellular carcinoma. Lancet 2003; 362: pp. 1907-1917.</p><li><p>5. Brown B.D., Geschwind F., Soulen M.C., et. al.: Society of interventional radiology position statement on chemoembolization of hepatic malignancies. J Vasc Interv Radiol 2006; 17: pp. 217-223.</p><li><p>6. BiAS. Für Windows, version 8.3 1989–2007. Dr. Hans Ackermann/Goethe Universität Frankfurt am Main, Germany.</p><li><p>7. Doffoël M., Bonnetain F., Bouché O., et. al.: Multicentre randomized phase III trial comparing tamoxifen alone or with transarterial Lipiodol chemoembolization for unresectable hepatocellular carcinoma in cirrhotic patients (Fédération Francophone de Cancérologie Digestive 9402). Eur J Cancer 2008; 44: pp. 528-538.</p><li><p>8. Seldinger S.I.: Catheter replacement of needle in percutaneous arteriography: a new technique. Acta Radiol 1953; 39: pp. 368-372.</p><li><p>9. Therasse P., Arbuck S.G., Eisenhauer E.A., et. al.: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: pp. 205-216.</p><li><p>10. Kaplan E.L., Meier P.: Nonparametic estimation from incomplete observation. J Am Stat Assoc 1958; 53: pp. 457-481.</p><li><p>11. Zangos S., Eichler K., Balzer J.O., et. al.: Large-sized hepatocellular carcinoma (HCC): a neoadjuvant treatment protocol with repetitive transarterial chemoembolization (TACE) before percutaneous MR-guided laser-induced thermotherapy (LITT). Eur Radiol 2007; 17: pp. 553-563.</p><li><p>12. Zang Z., Liu Q., He J., et. al.: The effect o preoperative transcatheter hepatic arterial chemoembolization on disease-free after hepatectomy for hepatocellular carcinoma. Cancer 2000; 31: pp. 2370-2377.</p><li><p>13. Vogl T.J., Straub R., Eichler K., et. al.: Malignant liver tumor treated with MR imaging-guided laser-induced thermotherapy: experience with complications in 899 patients (2,520 lesions). Radiology 2002; 225: pp. 367-377.</p><li><p>14. Nagasue N., Kohno H., Chang Y.C., et. al.: Liver resection for hepatocellular carcinoma. Results of 229 consecutive patients during 11 years. Ann Surg 1993; 217: pp. 375-384.</p><li><p>15. Nakashima T., Okuda K., Kojioro M., et. al.: Pathology of hepatocellular carcinoma in Japan: 232 consecutive cases autopsied in ten years. Cancer 1983; 51: pp. 863-877.</p><li><p>16. Nakamura H., Tanaka T., Hori S., et. al.: Transcatheter embolization of hepatocellular carcinoma: assessment of efficacy in cases of resection following embolization. Radiology 1983; 147: pp. 401-405.</p><li><p>17. Vogl T.J., Trapp M., Schroeder H., et. al.: Transarterial chemoembolization for hepatocellular carcinoma: volumetric and morphologic CT criteria for assessment of prognosis and therapeutic success—results from a liver transplantation center. Radiology 2000; 214: pp. 349-357.</p><li><p>18. Marelli L., Stigliano R., Triantos C., et. al.: Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007; 30: pp. 6-25.</p><li><p>19. Okuda K., Ohtsuki T., Obata H., et. al.: Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985; 56: pp. 918-928.</p><li><p>20. Zangos S., Gille T., Eichler K., et. al.: Transarterielle chemoembolisation bei hepatozellulären karzinomen: technik, indikationsstellung, ergebnisse. Der Radiologe 2001; 41: pp. 906-914.</p><li><p>21. Poyanli A., Rozanes I., Acunas B., et. al.: Palliative treatment of hepatocellular carcinoma by chemoembolization. Acta Radiol 2001; 42: pp. 602-607.</p><li><p>22. Llovet J.L., Real M.I., Montaña X., et. al.: Arterial embolization or chemoembolization versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet 2002; 359: pp. 1734-1739.</p><li><p>23. Kirchhoff T.D., Bleck J.S., Dettmer A., et. al.: Transarterial chemoembolization using degradable starch microspheres and iodized oil in the treatment of advanced hepatocellular carcinoma: evaluation of tumor response, toxicity, and survival. Hepatobil Pancreat Dis Int 2007; 3: pp. 259-266.</p><li><p>24. Varela M., Real M., Burrel M., et. al.: Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 2009; 46: pp. 474-481.</p></ul></div><div class="post-tail-wrapper text-muted"><div class="post-meta mb-3"> <i class="far fa-folder-open fa-fw mr-1"></i> <a href='/categories/academic-radiology/'>Academic Radiology</a>, <a href='/categories/volume-19/'>Volume 19</a>, <a href='/categories/issue-4/'>Issue 4</a></div><div class="post-tags"> <i class="fa fa-tags fa-fw mr-1"></i> <a href="/tags/journals/" class="post-tag no-text-decoration" >Journals</a> <a href="/tags/general-radiology/" class="post-tag no-text-decoration" >General Radiology</a></div><div class="post-tail-bottom d-flex justify-content-between align-items-center mt-3 pt-5 pb-2"><div class="license-wrapper"> This post is licensed under <a href="https://creativecommons.org/licenses/by/4.0/"> CC BY 4.0 </a> by the author.</div><div class="share-wrapper"> <span class="share-label text-muted mr-1">Share</span> <span class="share-icons"> <a href="https://twitter.com/intent/tweet?text=Retrospective%20Study%20on%20the%20Use%20of%20Different%20Protocols%20for%20Repeated%20Transarterial%20Chemoembolization%20in%20the%20Treatment%20of%20Patients%20with%20Hepatocellular%20Carcinoma%20-%20Radiology%20Tree&url=https%3A%2F%2Fclinicaltree.github.io%2Fposts%2Fretrospective-study-on-the-use-of-different-protocols-for-repeated-transarterial-chemoembolization-i%2F" data-toggle="tooltip" data-placement="top" title="Twitter" target="_blank" rel="noopener" aria-label="Twitter"> <i class="fa-fw fab fa-twitter"></i> </a> <a href="https://www.facebook.com/sharer/sharer.php?title=Retrospective%20Study%20on%20the%20Use%20of%20Different%20Protocols%20for%20Repeated%20Transarterial%20Chemoembolization%20in%20the%20Treatment%20of%20Patients%20with%20Hepatocellular%20Carcinoma%20-%20Radiology%20Tree&u=https%3A%2F%2Fclinicaltree.github.io%2Fposts%2Fretrospective-study-on-the-use-of-different-protocols-for-repeated-transarterial-chemoembolization-i%2F" data-toggle="tooltip" data-placement="top" title="Facebook" target="_blank" rel="noopener" aria-label="Facebook"> <i class="fa-fw fab fa-facebook-square"></i> </a> <a href="https://t.me/share/url?url=https%3A%2F%2Fclinicaltree.github.io%2Fposts%2Fretrospective-study-on-the-use-of-different-protocols-for-repeated-transarterial-chemoembolization-i%2F&text=Retrospective%20Study%20on%20the%20Use%20of%20Different%20Protocols%20for%20Repeated%20Transarterial%20Chemoembolization%20in%20the%20Treatment%20of%20Patients%20with%20Hepatocellular%20Carcinoma%20-%20Radiology%20Tree" data-toggle="tooltip" data-placement="top" title="Telegram" target="_blank" rel="noopener" aria-label="Telegram"> <i class="fa-fw fab fa-telegram"></i> </a> <i id="copy-link" class="fa-fw fas fa-link small" data-toggle="tooltip" data-placement="top" title="Copy link" data-title-succeed="Link copied successfully!"> </i> </span></div></div></div></div></div><div id="panel-wrapper" class="col-xl-3 pl-2 text-muted"><div class="access"><div id="access-lastmod" class="post"><div class="panel-heading">Recently Updated</div><ul class="post-content pl-0 pb-1 ml-1 mt-2"><li><a href="/posts/neurometabolites-alteration-in-the-acute-phase-of-mild-traumatic-brain-injury-mtbi/">Neurometabolites Alteration in the Acute Phase of Mild Traumatic Brain Injury (mTBI)</a><li><a href="/posts/reinforcing-the-importance-and-feasibility-of-implementing-a-low-dose-protocol-for-ct-guided-biopsie/">Reinforcing the Importance and Feasibility of Implementing a Low-dose Protocol for CT-guided Biopsies</a><li><a href="/posts/rethinking-the-pgy-1-basic-clinical-year/">Rethinking the PGY-1 Basic Clinical Year</a><li><a href="/posts/single-injection-dual-phase-cone-beam-ct-dp-cbct-vascular-anatomy-assessment-and-occult-nodule-det/">Single Injection Dual-Phase Cone Beam CT (DP-CBCT) Vascular Anatomy Assessment and Occult Nodule Detection; Have We Reached the Focus?</a><li><a href="/posts/the-yellow-scale-is-superior-to-the-gray-scale-for-detecting-acute-ischemic-stroke-on-a-monitor-disp/">The Yellow Scale Is Superior to the Gray Scale for Detecting Acute Ischemic Stroke on a Monitor Display in Computed Tomography</a></ul></div><div id="access-tags"><div class="panel-heading">Trending Tags</div><div class="d-flex flex-wrap mt-3 mb-1 mr-3"> <a class="post-tag" href="/tags/general-radiology/">General Radiology</a> <a class="post-tag" href="/tags/journals/">Journals</a></div></div></div><div id="toc-wrapper" class="pl-0 pr-4 mb-5"><div class="panel-heading pl-3 pt-2 mb-2">Contents</div><nav id="toc"></nav></div><script src="https://cdn.jsdelivr.net/npm/tocbot@4.20.1/dist/tocbot.min.js"></script></div></div><div class="row"><div id="tail-wrapper" class="col-12 col-lg-11 col-xl-9 pl-3 pr-3 pr-xl-4 mt-5"><div id="related-posts" class="mb-2 mb-sm-4"><h3 class="pt-2 mb-4 ml-1" data-toc-skip>Further Reading</h3><div class="card-deck mb-4"><div class="card"> <a href="/posts/a-new-approach-to-assess-intracranial-white-matter-abnormalities-in-glaucoma-patients/"><div class="card-body"> <em class="small" data-ts="1333213200" data-df="ll" > Mar 31, 2012 </em><h3 class="pt-0 mt-1 mb-3" data-toc-skip>A New Approach to Assess Intracranial White Matter Abnormalities in Glaucoma Patients</h3><div class="text-muted small"><p> Rationale and Objectives The aims of this study was to evaluate, using 3-T diffusion tensor imaging, changes of fractional anisotropy (FA) in the orbital and intracranial part of the optic nerve (...</p></div></div></a></div><div class="card"> <a href="/posts/baseline-suvmax-at-pet-ct-in-stage-iiia-non-small-cell-lung-cancer-patients-undergoing-surgery-after/"><div class="card-body"> <em class="small" data-ts="1333213200" data-df="ll" > Mar 31, 2012 </em><h3 class="pt-0 mt-1 mb-3" data-toc-skip>Baseline SUVmax at PET-CT in Stage IIIA Non-small-cell Lung Cancer Patients Undergoing Surgery after Neoadjuvant Therapy</h3><div class="text-muted small"><p> Rationale and Objectives To evaluate the prognostic significance of maximum standardized uptake value (SUVmax) at 18 F-fluorodeoxyglucose (FDG) positron emission tomography-computed tomography in...</p></div></div></a></div><div class="card"> <a href="/posts/correlations-between-suvmax-and-expression-of-glut1-and-growth-factors-inducing-lymphangiogenesis/"><div class="card-body"> <em class="small" data-ts="1333213200" data-df="ll" > Mar 31, 2012 </em><h3 class="pt-0 mt-1 mb-3" data-toc-skip>Correlations between SUVmax and Expression of GLUT1 and Growth Factors Inducing Lymphangiogenesis</h3><div class="text-muted small"><p> Rationale and Objectives The purpose of this study was to assess the correlations between the maximum standardized uptake value (SUVmax) of colorectal carcinoma and hepatocyte growth factor (HGF),...</p></div></div></a></div></div></div><div class="post-navigation d-flex justify-content-between"> <a href="/posts/radiology-history-lives/" class="btn btn-outline-primary" prompt="Older"><p>Radiology History Lives</p></a> <a href="/posts/shape-based-assessment-of-vertebral-fracture-risk-in-postmenopausal-women-using-discriminative-shape/" class="btn btn-outline-primary" prompt="Newer"><p>Shape-based Assessment of Vertebral Fracture Risk in Postmenopausal Women Using Discriminative Shape Alignment</p></a></div></div></div></div><div id="search-result-wrapper" class="d-flex justify-content-center unloaded"><div class="col-12 col-sm-11 post-content"><div id="search-hints"><div id="access-tags"><div class="panel-heading">Trending Tags</div><div class="d-flex flex-wrap mt-3 mb-1 mr-3"> <a class="post-tag" href="/tags/general-radiology/">General Radiology</a> <a class="post-tag" href="/tags/journals/">Journals</a></div></div></div><div id="search-results" class="d-flex flex-wrap justify-content-center text-muted mt-3"></div></div></div></div><footer><div class="container pl-lg-4 pr-lg-4"><div class="d-flex justify-content-between align-items-center text-muted ml-md-3 mr-md-3"><div class="footer-left"><p class="mb-0"> © 2023 <a href="https://twitter.com/username">Clinical Team</a>. <span data-toggle="tooltip" data-placement="top" title="Except where otherwise noted, the blog posts on this site are licensed under the Creative Commons Attribution 4.0 International (CC BY 4.0) License by the author.">Some rights reserved.</span></p></div><div class="footer-right"><p class="mb-0">Using the <a href="https://jekyllrb.com" target="_blank" rel="noopener">Jekyll</a> theme <a href="https://github.com/cotes2020/jekyll-theme-chirpy" target="_blank" rel="noopener">Chirpy</a>.</p></div></div></div></footer><div id="mask"></div><a id="back-to-top" href="#" aria-label="back-to-top" class="btn btn-lg btn-box-shadow" role="button"> <i class="fas fa-angle-up"></i> </a><div id="notification" class="toast" role="alert" aria-live="assertive" aria-atomic="true" data-animation="true" data-autohide="false"><div class="toast-header"> <button type="button" class="ml-2 ml-auto close" data-dismiss="toast" aria-label="Close"> <span aria-hidden="true">&times;</span> </button></div><div class="toast-body text-center pt-0"><p class="pl-2 pr-2 mb-3">A new version of content is available.</p><button type="button" class="btn btn-primary" aria-label="Update"> Update </button></div></div><script src="https://cdn.jsdelivr.net/npm/simple-jekyll-search@1.10.0/dest/simple-jekyll-search.min.js"></script> <script> SimpleJekyllSearch({ searchInput: document.getElementById('search-input'), resultsContainer: document.getElementById('search-results'), json: '/assets/js/data/search.json', searchResultTemplate: '<div class="pl-1 pr-1 pl-sm-2 pr-sm-2 pl-lg-4 pr-lg-4 pl-xl-0 pr-xl-0"> <a href="{url}">{title}</a><div class="post-meta d-flex flex-column flex-sm-row text-muted mt-1 mb-1"> {categories} {tags}</div><p>{snippet}</p></div>', noResultsText: '<p class="mt-5">Oops! No results found.</p>', templateMiddleware: function(prop, value, template) { if (prop === 'categories') { if (value === '') { return `${value}`; } else { return `<div class="mr-sm-4"><i class="far fa-folder fa-fw"></i>${value}</div>`; } } if (prop === 'tags') { if (value === '') { return `${value}`; } else { return `<div><i class="fa fa-tag fa-fw"></i>${value}</div>`; } } } }); </script> <script src="https://cdn.jsdelivr.net/combine/npm/magnific-popup@1.1.0/dist/jquery.magnific-popup.min.js,npm/lazysizes@5.3.2/lazysizes.min.js,npm/clipboard@2.0.11/dist/clipboard.min.js"></script> <script src="https://cdn.jsdelivr.net/combine/npm/dayjs@1.11.6/dayjs.min.js,npm/dayjs@1.11.6/locale/en.min.js,npm/dayjs@1.11.6/plugin/relativeTime.min.js,npm/dayjs@1.11.6/plugin/localizedFormat.min.js"></script> <script defer src="/assets/js/dist/post.min.js"></script> <script src="https://cdn.jsdelivr.net/npm/bootstrap@4.6.2/dist/js/bootstrap.bundle.min.js"></script> <script defer src="/app.js"></script> <script defer src="https://www.googletagmanager.com/gtag/js?id=G-L66SLQK23K"></script> <script> document.addEventListener("DOMContentLoaded", function(event) { window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-L66SLQK23K'); }); </script>
